Common Stock, par value $0.0001 per share
- Symbol
- DRMA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Dermata Therapeutics, Inc.
DRMANASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operation and Financial Condition. On August 11, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the quarter ended June 30, 2026, and provided a corporate update. A copy of the press release is furnished under Item 2.02 as Exhibit 99.1.…
Press release in this filing
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026 →Company context
Dermata Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing a first-of-its-kind skin renewal treatment which incorporates Dermata’s Bioneedle™. The Company expects to launch its first product on August 25, 2026, with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more information, or to join our mailing list, please visit http://www.dermatarx.com/.
Current securities
Historical securities (1)
Registered securities in this filing
DERMATA THERAPEUTICS, INC. · 8-K · Filed 2026-08-11
Warrants, exercisable for one share of Common Stock
- Symbol
- DRMAW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Historical · closed Aug 17, 2026
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02. Results of Operation and Financial Condition.
On
August 11, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding
its results of operations for the quarter ended June 30, 2026, and provided a corporate update. A copy of the press release is furnished
under Item 2.02 as Exhibit 99.1.
The
information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed”
for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange
Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange
Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference
into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such
filing.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026 - Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 - - Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand - SAN DIEGO, CA, August 11, 2026 - Dermata Therapeutics, Inc. (Nasdaq: DRMA ) (“Dermata,” or the “Company”), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026. “Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company,” commented Gerry Proehl, Dermata’s Chairman, President, and CEO. “This transition has been marked by significant execution across our organization, culminating in the development of our first commercial product, Tome Foundational Treatment, which we expect to start selling on August 25, 2026. As we prepare to enter the consumer skincare market, we believe we’ve identified the untapped ‘…
Open exhibit ↗